Results 71 to 80 of about 20,028 (211)

Metrnl: A Novel Therapeutic Target in Atherosclerosis

iNew Medicine, EarlyView.
ABSTRACT Atherosclerosis is a chronic inflammatory vascular disease and the main pathological basis of cardiovascular and cerebrovascular events. Exploration of endogenous protective factors in the disease is beneficial for the establishment of new therapeutic strategies.
Pin Wang, Dao‐Xin Wang, Chao‐Yu Miao
wiley   +1 more source

Proteomics‐Based Identification of the Pyroptosis‐Related Biomarker PCSK9 and Its Association With the Pathogenesis of Rheumatoid Arthritis

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Rheumatoid arthritis (RA) is a common autoimmune disease, and early diagnosis is critical for effective treatment. This study aims to identify potential biomarkers related to pyroptosis through serum proteomics analysis, offering new insights for the early diagnosis of RA.
Lei Wang, Hao‐Jie Chen, Ting‐Ting Wu, Xin‐Yi Shen, Ying‐Ying Gao, Yu‐Feng Yin, Tian Ren, Xin Chu, Jing Cao, Tao Cheng, Ming‐Jun Wang   +10 more
wiley   +1 more source

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

Lipids in Health and Disease, 2008
Background Proprotein convertase subtilisin kexin-like 9 (PCSK9) is a secreted glycoprotein that is transcriptionally regulated by cholesterol status. It modulates levels of circulating low density lipoprotein cholesterol (LDLC) by negatively regulating ...
Mbikay Majambu, LaHaye Stephen A, Lahey Karen A, Chaplin Anna, Cousins Marion, Raymond Angela, Dewpura Thilina, Mayne Janice, Ooi Teik, Chrétien Michel   +9 more
doaj   +1 more source

Mapping Causal Biology: Mendelian Randomization in the Era of Big Data

Med Research, EarlyView.
Mendelian randomization (MR) leverages genetic variants to mitigate confounding biases in causal inference. This review systematically maps MR's methodological evolution, highlights its expanding applications in epidemiology and drug target validation, and outlines future directions for overcoming current biases through dynamic, multi‐omics, and cross ...
Xuanlu Shen, Chunrun Qu, Zeyu Wang, Jinglin Zhou, Hongwei Liu, Yingjie Li, Bowei Liu, Hao Zhang, Nan Zhang, Jingwei Zhang, Quan Cheng   +10 more
wiley   +1 more source

Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation

Neuroprotection, EarlyView.
Abstract Prime editing, a novel clustered regularly interspaced short palindromic repeats (CRISPR)‐based technology, fuses a reverse transcriptase (RT) to an engineered CRISPR‐associated protein 9 (Cas9) and uses a prime editing guide RNA (pegRNA)‐encoded template.
Tianshan Ji, Yuan Zhang, Jinyi Zhao, Yiping Lu, Chengkun Wang   +4 more
wiley   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Regulation of PCSK9 by nutraceuticals

Pharmacological Research, 2017
PCSK9 (proprotein convertase subtilisin kexin type 9) is a liver secretory enzyme that regulates plasma low-density lipoprotein (LDL) cholesterol (LDL-C) levels through modulation of LDL receptor (LDLR) density on the surface of hepatocytes. Inhibition of PCSK9 using monoclonal antibodies can efficiently lower plasma LDL-C, non-high-density lipoprotein
Momtazi, Amir Abbas, Banach, Maciej, PIRRO, Matteo, Katsiki, Niki, Sahebkar, Amirhossein   +4 more
openaire   +3 more sources

Targeting PCSK9 in Vascular Smooth Muscle Cells: An Effective Strategy to Suppress Ferroptosis and Attenuate Abdominal Aortic Aneurysm Progression

Cell Proliferation, EarlyView.
PCSK9 aggravates AAA by promoting ferroptosis in VSMCs. In the pathological AAA environment, PCSK9 upregulation triggers ferritinophagy‐dependent degradation of FTH1, leading to Fe2+ release, triggering lipid peroxidation and ferroptosis, exacerbating AAA.
Mengdie Xia, Man Li, Yanyu Chen, Jialin Chen, Yuting Cui, Xi‐Long Zheng, Jing Yang, Bingzhao Li, Xiaofeng Ma, Miao Liu, Gang Fan, Juan Peng, Xiaoyan Dai, Zhihan Tang   +13 more
wiley   +1 more source

Genetic screening and response to drug therapy in familial hypercholesterolemia

Frontiers in Molecular Biosciences
ObjectivesFamilial hypercholesterolemia (FH) is an autosomal genetic disorder, which is significantly underdiagnosed. Here, we aimed to identify the genetic causes of a FH family and clarify the clinical diagnosis of the patient and then provide ...
Yuzhi Lu, Yuzhi Lu, Yuzhi Lu, Qianwen Chen, Qianwen Chen, Qianwen Chen, Qianwen Chen, Wenjuan Zhang, Wenjuan Zhang, Wenjuan Zhang, Wenjuan Zhang, Jiangtao Dong, Jiangtao Dong, Jiangtao Dong, Jiangtao Dong, Lingfeng Zha, Lingfeng Zha, Lingfeng Zha   +17 more
doaj   +1 more source